St. Jude Medical (NYSE:STJ) (St. Paul, Minnesota) has been given the green light by the FDA to resume its IDE trial evaluating the Portico Transcather Aortic Valve Implantation (TAVI) System. The trial, which started in May of last year, was put on hold the following September, due to concerns about reduced leaflet mobility in patients implanted with Portico.